Multiple treatment strategies for NPC have been investigated through clinical trials, including EGFR inhibitors, PI3K/Akt inhibitors, inhibitors of angiogenesis, and other, however no drug has been approved for the treatment of NPC. Here, AKT1 is linked to nasopharyngeal carcinoma.